甲基1-甲酰基环丁烷羧酸酯 | 155380-49-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甲基1-甲酰基环丁烷羧酸酯
• 英文名称: methyl 1-formylcyclobutanecarboxylate
• 英文别名: methyl 1-formylcyclobutane-1-carboxylate
• CAS: 155380-49-7
• 化学式: C₇H₁₀O₃
• 分子量: 142.155
• InChiKey: ZWKZWJDTPRZFLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲基1-甲酰基环丁烷羧酸酯 在 lithium hydroxide monohydrate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 30.08h， 生成 1-[(dimethylamino)methyl]cyclobutanecarboxylic acid
  参考文献：
  名称：

  [EN] TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS
  [FR] AGENTS DE DÉGRADATION TRICYCLIQUES D'IKAROS ET D'AIOLOS

  摘要：

  三环脑蛋白结合剂通过泛素蛋白酶体途径降解Ikaros或Aiolos以用于治疗应用的描述。

  公开号：

  WO2020210630A1
• 作为产物：
  描述：

  1,1-环丁基二甲酸 在 硫酸 、 二异丁基氢化铝 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 甲基1-甲酰基环丁烷羧酸酯
  参考文献：
  名称：

  Tetramethyl 1,1,4,4-cyclohexanetetracarboxylate: preparation and conversion to key precursors of fluorinated, stereochemically defined cyclohexanes

  摘要：

  Stereoselective low-temperature diisobutylaluminum hydride (DIBALH) reduction of the title tetraester 3 affords trans-1,4-dialdehyde 4a as the major product. Fluorination of 4a,b, followed by additional elaboration leads to novel, 1,1,4,4-tetrasubstituted cyclohexanes bearing trans-1,4-difluoromethyl and fluoromethyl groups. The effect of ring size and number of ester substituents on the outcome of the reduction has been examined and treatment of dimethyl 1,1-cycloalkyl diesters 7a-c with excess DIBALH results in reduction of only one ester group. An entry into trans-1,4-trifluoromethylated tetrasubstituted cyclohexanes has been gained through stereoselective SF4 fluorination of 1,1,4,4-cyclohexanetetracarboxylic acid 17. Stereochemical assignments are supported by X-ray crystallographic data.

  DOI：

  10.1021/jo00076a055

文献信息

• Benzimidazolone carboxylic acid derivatives
  申请人：Ando Koji

  公开号：US20050277671A1

  公开（公告）日：2005-12-15

  This invention relates to compounds of the formula (I): wherein R 1 , R 2 , R 3 , A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

  这项发明涉及以下式（I）的化合物： 其中R1、R2、R3、A和m如本文所述，或其药学上可接受的盐或溶剂，以及含有这种化合物的组合物和利用这种化合物治疗由5-HT4受体活性介导的疾病的用途，例如但不限于胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病如心力衰竭和心律失常、糖尿病和呼吸暂停综合征。
• Oxyindole derivatives
  申请人：Uchida Chikara

  公开号：US20060194842A1

  公开（公告）日：2006-08-31

  This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R 1 , R 2 , R 3 , R 4 and R 5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.

  这项发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中： A，R1，R2，R3，R4和R5分别如本文所述或药学上可接受的盐，以及含有这种化合物的组合物和利用这种化合物治疗由5-HT 4 激动活性介导的疾病的用途，例如但不限于胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病或呼吸暂停综合征。
• [EN] ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D'ANDROGÈNES ET LEURS UTILISATIONS
  申请人：SUZHOU KINTOR PHARMACEUTICALS INC

  公开号：WO2012119559A1

  公开（公告）日：2012-09-13

  Disclosed are substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds. The compounds and compositions can be used for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss and hypertrichosis.

  本申请公开了替代噻嗪唑烷酮化合物和包含这种化合物的药物组合物。这些化合物和组合物可用于治疗与雄激素受体相关的疾病或疾病，如前列腺癌、良性前列腺肥大、男性脱发和多毛症。
• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：INCYTE CORPORATION

  公开号：US20150225401A1

  公开（公告）日：2015-08-13

  The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及环丙胺衍生物，其为LSD1抑制剂，可用于治疗癌症等疾病。
• Benzisoxazole Derivatives
  申请人：Noguchi Hirohide

  公开号：US20080207690A1

  公开（公告）日：2008-08-28

  This invention relates to compounds of the formula (I): wherein A, B, R 1 , R 4 , m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

  本发明涉及化合物的公式（I）：其中A，B，R1，R4，m和n分别如本文所述或其药学上可接受的盐，并包含这些化合物的组合物以及这些化合物在治疗由5-HT4受体活性介导的疾病中的使用，例如但不限于胃食管反流病，胃肠道疾病，胃动力障碍，非溃疡性消化不良，功能性消化不良，肠易激综合症（IBS），便秘，消化不良，食管炎，胃食管疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病，如心力衰竭和心律失常，糖尿病和呼吸暂停综合症。